Table 1.
Author | Recruitment site | Design | Study period | Sample size (Intervention/Control) | Intervention(s) | Comparison(s) | Measurement tools | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Breakdown | Total (for each participant) | Full analysis set | Per-protocol | Outcome | Compliance | Safety and tolerability | |||||
Woelk & Schlafke (2009)35 Germany |
General practitioner’s clinics | Multi-centre, double-blind, randomised phase III study | 1 week screening phase, 6 weeks treatment phase, 2 weeks discontinuation phase. | 9 weeks | 40/37 | 36/33 | 80 mg Silexan capsule + Lorazepam placebo once daily during 6-week treatment phase, and on day 43,45,47,50 and 53 during the discontinuation phase. | 0.5 mg Lorazepam capsule + Silexan placebo once daily during 6-week treatment phase, and on day 43,45,47,50 and 53 during the discontinuation phase. | Hamilton Anxiety Rating Scale (HAMA total score) | Method was not reported | Adverse events (AE) reported, physical and ECG examinations, vital signs, routine laboratory measurements |
Kasper et al. (2015)38 Germany |
17 general and psychiatric practices | Randomized, double-blind trial | Single-blind screening and wash-out phase of 3–7 days, followed by 10 weeks treatment phase. Post-baseline efficacy and safety assessments performed every 2 weeks | 11 weeks | 86/84 | 73/65 | 80 mg Silexan capsule once daily | Placebo capsules with 1/1000 the amount of lavender oil in Silexan capsules (to match the smell of Silexan capsules) once daily | Hamilton Anxiety Rating Scale (HAMA total score) | Compared the number of unused capsules returned by the patients to the expected number assuming a fully protocol compliant intake | Adverse events (AE) reported spontaneously, physical and ECG examinations, vital signs, routine laboratory measurements |
Kasper, et al. (2016)39 Germany |
35 psychiatric practices | Double-blind, randomized, placebo-controlled, parallel-group multicentre trial | Screening period of 3–7 days, followed by 10 weeks treatment phase. Efficacy and safety assessments performed at 1 and 2 weeks ± 2 days, as well as at 4, 7 and 10 weeks ± 7 days after baseline | 11 weeks | 159/156 | 141/128 | 80 mg Silexan capsule once daily | Placebo capsules with 1/1000 the amount of lavender oil in Silexan capsules (to match the smell of Silexan capsules) once daily | Hamilton Anxiety Rating Scale (HAMA total score) | Assessed by counting of returned medication | Adverse events (AE) reported, physical and ECG examinations, vital signs, routine laboratory measurements |
Kasper, et al. (2014)37 Germany |
57 psychiatric and general practices | Randomized, double-blind, double-dummy, multi-centre trial with four parallel groups | Screening and wash-out phase of 3–7 days, followed by 10 weeks treatment phase. Efficacy and safety assessments performed after 2, 4, 6, 8 and 10 weeks. Treatment phase is followed by 1 week down-titration phase for paroxetine withdrawal | 12 weeks | 121 (Silexan 160 mg/d)/13 5 (Silexan 80 mg/d)/132 (paroxetine)/135 (placebo) | 103 (Silexan 160 mg/d)/119 (Silexan 80 mg/d)/114 (paroxetine)/114 (placebo) | 160 mg Silexan capsule once daily; 80 mg Silexan capsule once daily. | 20 mg Paroxetine capsule; placebo capsule. | Hamilton Anxiety Rating Scale (HAMA total score) | Assessed by medication counting | Adverse events (AE) reported spontaneously, physical examinations, routine laboratory measurements. Withdrawal symptoms ascertained by administering the Physician Withdrawal Checklist (PWC-20) at the end of treatment phase and down-titration phase. |
Kasper, et al. (2010)36 Germany |
27 general and psychiatric primary care centres | Randomized, double-blind, placebo controlled, multi-centre trial | Single-blind placebo screening and wash-out phase of 3–7 days, followed by 10 weeks treatment phase. Post-baseline efficacy and safety assessments performed every 2 weeks | 12 weeks | 104/108 | 87/90 | 80 mg Silexan capsule daily | Placebo capsules with 1/1000 the amount of lavender oil in Silexan capsules (to match the smell of Silexan capsules) once daily | Hamilton Anxiety Rating Scale (HAMA total score) | Method was not reported | Adverse events (AE) reported, physical and ECG examinations, vital signs, routine laboratory measurements |